A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Amy Sehnert, MD
MyoKardia, Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Arizona
Scottsdale, Arizona, United States
- Yale New Haven Hospital
New Haven, Connecticut, United States
- Tufts Medical Center
Boston, Massachusetts, United States
- Washington University St. Louis
St Louis, Missouri, United States
- Duke Health Center at Southpoint
Durham, North Carolina, United States
- Oregon Health and Science University
Portland, Oregon, United States
- Hospital of the University of Pennsylvania (penn Heart and Vascular Center)
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2016
- Primary completion
- 30 Nov 2017
- Completion
- 30 Nov 2017
- Last update posted
- 8 Jun 2021
- Registered enrollment
- 21
- Registry id
- NCT02842242
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.